Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced that the FDA has updated the label for Dupixent (dupilumab) for the indication of atopic dermatitis.Per the latest FDA update, efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement will be added to the existing label.The label update is based on data from the late-stage LIBERTY-AD-HAFT study, which evaluated the efficacy and safety of Dupi ...